key: cord-1035511-c8hpgmz9
authors: Liu, Daniel; Cheng, Qiuye; Suh, Hye Rim; Magdy, Mark; Loi, Ken
title: The Role of Bariatric Surgery in a COVID-19 Era: A Review of Economic Costs
date: 2021-07-26
journal: Surg Obes Relat Dis
DOI: 10.1016/j.soard.2021.07.015
sha: bceed1ccde1422c1c6f6a4d446b9cf60f9813599
doc_id: 1035511
cord_uid: c8hpgmz9

Obesity has rapidly become a significant public health issue. As the prevalence of obesity continues to rise, so does its economic burden as a result of both direct and indirect costs. Likewise, since 2019, the coronavirus disease of 2019 (COVID-19) has become a global pandemic with rising infection rates carrying significant economic costs associated with treatment of the disease and the reduction in economic activity due to government regulations. The COVID-19 pandemic has had a detrimental impact on obesity, not only creating an increasingly obesogenic environment but also reducing access to bariatric care and treatment of obesity-related diseases. In this article, we form a compelling argument for the resumption of bariatric services as soon as it is safe to do so because bariatric surgery brings significant additional medical and economic benefits. Medically, obesity is a risk factor for increased severity of COVID-19 infections, and therefore, treatment of obesity should be a priority in the current pandemic. Additionally, bariatric surgery has been shown to be a cost-saving procedure in the long term and thus has significant economic benefit in reducing the costs of obesity in the future as we recover from the economic collapse following the global pandemic.

Obesity has rapidly become a global health concern, reaching pandemic proportions with worldwide obesity tripling over the last two decades 1 . Continual growth trend will result in an estimate of 50% of the worldwide population being overweight or obese by 2030 2 . Obesity is 5 associated with a number of comorbidities and chronic diseases including type 2 diabetes mellitus, cardiovascular diseases and cancer 3 as well as more frequent visits to their general practitioner or hospital 4 . Since the coronavirus disease (COVID-19) first emerged in late 2019, the virus has infected 144 million people worldwide with a current mortality rate of 3 million people 5 . The economic impact of obesity and COVID-19 are and will continue to be substantial 10 if uncurbed. This paper aims to discuss the economic burden of COVID-19 and obesity, while exploring the financial and health implications of bariatric surgery within this current climate.

We performed a thorough search of the literature for the purpose of this review. Our search criteria were directed to address the following topics: 1) the economic impact of obesity; 2) the economic impact of COVID-19; 3) the financial implications of bariatric surgery and 4) the impact of COVID-19 on obesity. These issues were explored by examining empirical articles 20 located through a computerized search of biomedical and life sciences databases (PubMed and Medline) and references located within the articles themselves. Articles were included based on relevance to the intended topic and date of publication was limited to the last ten years. The PRISMA guidelines were used to aid in evaluating the articles.

Our search terms included : 25 J o u r n a l P r e -p r o o f such as diabetes [9] [10] [11] . In 2005, the cost of overweight and obesity was $USD14.2 billion in Australia, with an additional $USD24.3 billion being spent on government subsidies for people who were overweight or obese, accounting for 4% of total GDP 12 . The global obesity pandemic extends beyond developed nations, with epidemiological evidence from Brazil in 2011 estimating that annual costs of obesity and their related diseases amounts to $USD269.6 billion, 55

representing 10.3% of their GDP 13 . As evident by a German study that showed a 70% increase in obesity related economic costs over a six year period 14 , the obesity problem and its associated economic impact will only continue to rise unless it is adequately addressed. A key application of economics involves decision making in order to ensure the efficient allocation of finite resources to maximize productivity. These choices involve minimizing opportunity costs and 60 ensuring optimal cost effectiveness 15 .

In addition to the overwhelming health and social impact, COVID-19 has led to great losses for the global economy. These costs include direct costs such as the cost of healthcare associated with treating patients affected by COVID-19 as well as numerous indirect costs such as unemployment, loss of productivity and income due to isolation measures, long-term complications such as cardiac or respiratory diseases, and mental health issues 16, 17 . In the first 70 half of 2020, most countries began enforcing stringent lockdown measures to reduce the spread contraction in the global economy with global GDP falling by 3.3% in 2020. Advanced economies including USA and Europe experienced an average fall of 4.7% in their GDP while emerging markets and developing economies were also affected, with an average decrease in GDP of 2.2% 17 . An out-of-equilibrium analysis of both direct costs of the COVID-19 lockdowns and the follow on effects of this through the global economy estimated that total 80 impact of COVID-19 amounts to 9% of global GDP 18 . Global output was also affected by intercountry interactions, with world trade volumes, industrial production and manufacturing purchasing managers' index falling steeply. This has been exacerbated by falling commodity prices, particularly petroleum, where weak aggregate demand has driven prices down 17 .

Inversely coupling the reduction of economic growth and output was the astronomical rise in 85 COVID-19 related health costs 19 . Table 2 summarizes the several papers which have attempted to estimate the current costs of the COVID-19 pandemic, despite the lack of reliable and unequivocal data. One paper estimated losses of COVID-19 in the USA to be approximately $USD16 trillion, representing 90% of the US GDP. Approximately half this cost is attributable to income lost from the COVID-19-induced recession and the remainder is from the economic 90 losses associated with COVID-19 related health related complications 20 . In China for the period January to March 2020, the total estimated healthcare and societal costs associated with COVID-19 were $USD0.47 billion and $USD383.02 billion respectively. Societal costs were primarily due to lost work days due to lockdown regulations 21 . One simulated model of the COVID-19 economic impact in the US estimated that a single symptomatic COVID-19 95 infection would cost a median of $USD3,045 in direct healthcare costs at the time of infection 22 . In Australia, the Treasury reported spending $USD101 billion on direct fiscal support in response to COVID-19 23 .

Despite the rise in health care need during COVID-19, some early trends on health spending have demonstrated a greater emphasis in budget allocation to supporting and boosting economic activity as oppose to funding of heath care. In high income countries, the budget 105 allocated to the health response for COVID-19 represents only 8% of pre-COVID-19 public health spending which equates to approximately $USD205 per capita 19 . Furthermore, the redistribution of health resources and personnel to running COVID-19 clinics and COVID related investigations/treatments have inadvertently impacted on the delivery of other medical services including elective surgery 24, 25 . In the context of obesity and bariatric surgery in 110 particular, the International Federation for the Surgery of Obesity and Metabolic Disorders issued a series of recommendations at the start of the COVID-19 pandemic. These recommendations stated that all elective surgeries should be postponed during the pandemic and rescheduled for when the pandemic is over 26 . The American Society for Metabolic and Bariatric Surgery (ASMBS) declares that bariatric surgery is not elective as it is the best, life-115 saving treatment for obesitya contradiction of the definition of elective which refers to a surgery that is not essential to the survival of the patient. Instead, the ASMBS advocates for the use of the term "medically necessary time-sensitive surgery" or "medically necessary nonemergent surgery" over the term "elective" when describing bariatric surgery and therefore advocates for bariatric/metabolic surgery to be restarted as soon as it is safe to do so 27 . 120

The reduction of face-to-face clinical care has also impacted on the care of chronic diseases such as hypertension and diabetes, which will likely have associated long-term costs, especially in obese patients. A world-wide survey among bariatric surgeons found that 84.6% of surgeons had postponed primary or redo bariatric procedures in light of the COVID-19 pandemic 28 . A 125 similar survey in the UK found that 97% of bariatric surgeons ceased their outpatient clinics for both new and follow-up patients and almost 60% of bariatric surgeons stopped placing new patients on their waiting lists 29 . In Argentina, a survey found that 99% of bariatric surgeons ceased all their elective bariatric surgeries, with a mean of 7.7 days prior to the first regional case 30 . 130

In addition, social distancing regulations and lockdown laws combined with socioeconomic stressors and deterioration of mental wellbeing may bear long-term consequences on obesity. This is due to the social isolation exacerbating socioeconomic stressors and reducing mental wellbeing, which may lead to altered eating patterns and an increase in sedentary lifestyles 31-34 135 the perfect milieu for obesity. With added financial stress, patients who were planning to seek out obesity surgery may now choose to delay treatment in the view of diverting their own personal resources to more urgent needs. Thus, while the COVID-19 regulations are effective at reducing the spread of the virus, they may serve as a risk factor for obesity and other associated metabolic diseases 35 . 140

Bariatric surgery remains the gold standard treatment for obesity and has been consistently 145 proven to be efficacious and safe 36,37 while also reducing incidence of obesity related comorbidities 38 . However, bariatric procedures are not inexpensive, with the median cost for a sleeve gastrectomy, a popular bariatric procedure, being $USD10,531 in 2013 39 . Despite these costs, a 2019 meta-analysis found that bariatric surgery when compared to conventional methods of weight loss is more cost saving over the life course, even when indirect costs were 150 J o u r n a l P r e -p r o o f not considered 40 . These results were consistent with a separate systematic review in 2018 41 , supporting the fact that bariatric surgery is highly cost-effective. The long-term financial benefits of bariatric surgery with regards to improvements or resolution of obesity and its associated metabolic diseases cannot be underestimated. At an individual level, metabolic surgery has been proven to significantly reduce daily medication-related healthcare costs for 155 patients previously requiring multi-drug therapy 40 . At a national healthcare level, the reversal of obesity associated chronic medical diseases such as diabetes, hypercholesterolemia and hypertension will significantly reduce the long-term health care burden which would continue to be present if untreated. A cost-utility analysis conducted in the United Kingdom substantiated that bariatric surgery produced annual savings per patient of $USD2689 while 160 providing an additional 0.8 life-years and 4.0 quality-adjusted life-years 42 . This supports the conclusion that bariatric surgery can save the healthcare system significant funds in the longterm.

Obesity remains a disease that must be treated in order to optimize health outcomes for patients. This is especially true in light of the COVID-19 pandemic, where obesity serves as a risk factor for increased severity of symptoms from COVID-19 viral infections. Obesity was associated 170 with increased need for hospitalization, mechanical ventilation, and increased mortality rates 43 .

This may be explained due to the decreased respiratory system compliance and functional capacity, as well as increased incidence of comorbidities such as cardiac disease 44 . In fact, one report on COVID-19 found that obesity was a more significant risk factor for hospital admission than cardiovascular disease 45 . In a recent systematic review on obesity and COVID-175 19, obesity was shown to have a significant association to higher COVID-19 infection rates (OR 1.50, P<0.001), more severe COVID-19 disease (OR 3.13, 95%; P=0.005) and higher mortality (OR 1.36, 95% P = 0.006) 43 . Bariatric surgery again has an important role in managing obesity-related COVID-19 complications, with one multi-center study finding that patients who have undergone bariatric surgery 12 months or earlier developed less severe 180 COVID-19-related symptoms than subjects who were currently obese 46 . Therefore, while the COVID-19 pandemic justly halted elective bariatric surgeries, efforts must be made to prioritize bariatric surgeries once it is practical to do so 47 .

The era of COVID-19 has had a broad impact on all aspects of society, economy, health infrastructure and politics. Similarly, the growing global trend and negative impact of obesity cannot be ignored. By objectively inspecting population trends 1 , it is clear that the obesity 190 pandemic remains an existing significant health care problem, while further compounding the effects of COVID-19. The global economic impact of both, when considered individually or as a collective, is enormous and both diseases must be tackled simultaneously. Even prior to COVID-19, bariatric surgery was under-utilized secondary to misconceptions and stigma associated with obesity and bariatric surgery 48 . Such perceptions may further delay suitable 195 candidates for bariatric surgery with the diversion of health resources in managing COVID-19.

As previously discussed in our article, the financial impact of obesity surgery as a secondary prevention of obesity related metabolic disease cannot and should not be ignored as it has long standing benefits when it comes to health care not only in the COVID era but beyond.

As we come to terms with COVID-19 and the recommencement of elective surgery, adequate financial resources should be allocated to dealing with the backlog of patients currently awaiting bariatric surgery worldwide. The prioritization of case load needs to be considered carefully so as to ensure that available resources are allocated to patients who will benefit most from bariatric surgery in addition to their BMI. In so doing, we also help to maximally 205 minimize future healthcare burden relating to their obesity disease. Fundamentally, this will include bariatric patients with significant morbidity and mortality from their associated obesity related diseases (i.e., cardiovascular, respiratory and metabolic disease). In addition to metabolic disease, bariatric surgery should also be preferentially offered to patients who have had their quality of life and mobility affected by organ specific disease (i.e., chronic kidney 210 disease, chronic liver disease and obstructive sleep apnea) and symptoms relating to high BMI (i.e., Musculo-skeletal, joint problems).

It is clear that COVID-19 has caused a significant impact on global economic output and severely reduced economic growth. While the exact costs cannot yet be quantified, the economic and social costs from the disease are profound and will take many years to recover from. COVID-19 has also become a significant risk factor in potentiating the obesity pandemic, 220 while obesity is in itself a risk factor in exacerbating the severity of COVID-19 infections.

Thus, while COVID-19 has currently limited the practice of bariatric surgery, adequate focus and attention needs to be allocated to prioritize bariatric surgery once it is safe to do so, as it serves to not only reduce obesity-related complications but also scale down economic and social costs going into the future. 225 J o u r n a l P r e -p r o o f Abbreviations: Rretrospective/ Pprospective J o u r n a l P r e -p r o o f Abbreviations: Rretrospective/ PAprospective analysis J o u r n a l P r e -p r o o f

Overcoming obesity: an initial economic analysis

Multiple risk factors for cardiovascular disease and diabetes mellitus

Obesity impacts on general practice appointments

The effect of obesity on direct medical costs in total knee arthroplasty

Economic impact of adult obesity on health systems: a systematic review

The economic burden of ill health due to diet, physical inactivity, smoking, alcohol and obesity in the UK: an update to 2006-07 NHS costs

The medical care costs of obesity: an instrumental variables approach

The cost of overweight and obesity in Australia

Direct healthcare cost of obesity in Brazil: an application of the cost-of-illness method from the perspective of the public health system in 2011

Health burden and costs of obesity and overweight in Germany: an update. The European journal of health economics 16

What is cost-effectiveness?

Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis of follow-up studies

The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States

The Treasury, ACT, 2020)

World economic outlook

Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19. (World Health Organisation Geneva

Recommendations for Metabolic and Bariatric Surgery During the COVID-19 Pandemic from IFSO

Safer through surgery: American Society for Metabolic and Bariatric Surgery statement regarding metabolic and bariatric surgery during the COVID-19 pandemic

The Impact of the COVID-19 Pandemic on Bariatric Surgery

Systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. Surgery for Obesity and Related Diseases

Cost-utility analysis of bariatric surgery

Obesity in COVID-19: a systematic review and meta-analysis

Obesity and its Implications for COVID-19 Mortality

Effects of Bariatric Surgery on COVID-19: a Multicentric Study from a High Incidence Area

The Impact of COVID-19 Pandemic on Obesity and Bariatric Surgery

Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery